Sihuan Pharmaceutical Holdings Group Ltd. (SEHK:460) commences share repurchases on June 24, 2024, under the program mandated by the shareholders in the Annual General Meeting held on June 7, 2024. As per the mandate the company is authorized to repurchase up to 932,999,920 shares, representing 10% of its issued share capital. The purpose of repurchase program is to enhancement of the net assets and/or earning per share of the company.

The repurchases will be made out of the funds legally available for the purpose in accordance with the Bye-Laws, the listing rules and the applicable laws of Bermuda. The company will cancel any repurchased shares and/or hold the repurchased shares as treasury shares for future sale or transfer. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is carried out to the full extent, unless varied or revoked in a General Meeting.

As of June 7, 2024, the company has 9,329,999,206 shares in issue.